Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Nexcella, Inc.

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
From Nexcella, Inc.
Via GlobeNewswire
Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
From Nexcella, Inc.
Via GlobeNewswire
U.S. Food and Drug Administration Approves Orphan Drug Designation for Nexcella NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
From Nexcella, Inc.
Via GlobeNewswire
Nexcella to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board
From Nexcella, Inc.
Via GlobeNewswire
U.S. Food and Drug Administration Approves Orphan Drug Designation for NXC-201 as a Treatment for Multiple Myeloma
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
From Nexcella, Inc.
Via GlobeNewswire
Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
From Nexcella, Inc.
Via GlobeNewswire
Nexcella announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
From Nexcella, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.